Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 45Sarcoma 6Tumor-Agnostic 4Genitourinary 4Thoracic 2Head & Neck 2CNS 2Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × regorafenib × Genitourinary × Clear all
NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Bayer

Phase 2 Completed
6 enrolled 11 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

SCRI Development Innovations, LLC

Phase 2 Completed
100 enrolled 14 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT00664326 2021-01-29

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Bayer

Phase 2 Completed
49 enrolled 20 charts
Genitourinary

Carcinoma, Renal Cell

NCT02459119 2020-08-06

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

University of Alabama at Birmingham

Phase 2 Completed
17 enrolled 11 charts
Genitourinary

Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡